5-Amino-1-hydroxymethyl-cyclohexane-1,2,3,4-tetraol

ID: ALA222396

Chembl Id: CHEMBL222396

Max Phase: Preclinical

Molecular Formula: C7H15NO5

Molecular Weight: 193.20

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Synonyms: Valinolamine | Valiolamine

Canonical SMILES:  N[C@H]1C[C@](O)(CO)[C@@H](O)[C@H](O)[C@H]1O

Standard InChI:  InChI=1S/C7H15NO5/c8-3-1-7(13,2-9)6(12)5(11)4(3)10/h3-6,9-13H,1-2,8H2/t3-,4-,5+,6-,7-/m0/s1

Standard InChI Key:  VDLOJRUTNRJDJO-ZYNSJIGGSA-N

Alternative Forms

  1. Parent:

    ALA222396

    VALIOLAMINE

Associated Targets(Human)

MGAM Tclin Maltase-glucoamylase (654 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SI Tchem Sucrase-isomaltase (84 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
GAA Tclin Lysosomal alpha-glucosidase (35701 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
GBA1 Tclin Beta-glucocerebrosidase (14647 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Gaa Acidic alpha-glucosidase (551 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Si Sucrase-isomaltase (908 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
AGL Glycogen debranching enzyme (11 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
Vero (26788 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
dengue virus type 1 (258 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SARS-CoV-2 (38078 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: YesOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 193.20Molecular Weight (Monoisotopic): 193.0950AlogP: -3.48#Rotatable Bonds: 1
Polar Surface Area: 127.17Molecular Species: BASEHBA: 6HBD: 6
#RO5 Violations: 1HBA (Lipinski): 6HBD (Lipinski): 7#RO5 Violations (Lipinski): 1
CX Acidic pKa: 12.46CX Basic pKa: 8.51CX LogP: -3.96CX LogD: -5.10
Aromatic Rings: 0Heavy Atoms: 13QED Weighted: 0.26Np Likeness Score: 2.74

References

1. Horii S, Fukase H, Matsuo T, Kameda Y, Asano N, Matsui K..  (1986)  Synthesis and alpha-D-glucosidase inhibitory activity of N-substituted valiolamine derivatives as potential oral antidiabetic agents.,  29  (6): [PMID:3519969] [10.1021/jm00156a023]
2. Kuriyama C, Kamiyama O, Ikeda K, Sanae F, Kato A, Adachi I, Imahori T, Takahata H, Okamoto T, Asano N..  (2008)  In vitro inhibition of glycogen-degrading enzymes and glycosidases by six-membered sugar mimics and their evaluation in cell cultures.,  16  (15): [PMID:18595718] [10.1016/j.bmc.2008.06.026]
3. Karade SS, Hill ML, Kiappes JL, Manne R, Aakula B, Zitzmann N, Warfield KL, Treston AM, Mariuzza RA..  (2021)  N-Substituted Valiolamine Derivatives as Potent Inhibitors of Endoplasmic Reticulum α-Glucosidases I and II with Antiviral Activity.,  64  (24.0): [PMID:34870992] [10.1021/acs.jmedchem.1c01377]

Source